Adaptogenic Herbs

Adaptogens are a pharmacological class — not an INCI entity — defined by non-specific HPA-axis modulation. Ashwagandha (Withania somnifera) withanolides downregulate cortisol-induced MMP activity and inhibit NF-κB signalling in keratinocytes; Rhodiola rosea salidroside and rosavin scavenge ROS and protect mitochondrial membrane potential under oxidative load; Reishi (Ganoderma lucidum) ganoderic-acid triterpenoids and beta-glucans engage dectin-1 receptors on Langerhans cells, dampening neurogenic inflammation. Topical activity is real in vitro but penetration of large triterpenoid glycosides is the rate-limiting step.

0.1–2% standardised extract (look for withanolide ≥1.5% or rosavin ≥3%)

Typically delivered via biofermentation or standardized extracts to guarantee active compound concentrations.

Adaptogen marketing dramatically outpaces topical clinical evidence — favor brands citing standardized actives (withanolide %, rosavin %).

The adaptogen-skincare category leans heavily on the oral-supplement evidence base, which does not transfer to topical use. 'Cortisol-reducing cream' claims are mechanistically speculative — keratinocytes synthesise cortisol locally, but whether a topical adaptogen modulates systemic or even cutaneous cortisol in a clinically meaningful way is unresolved. Wild-harvest pressure on rhodiola in particular has prompted CITES discussion.

Sold as a 'stress-skincare' wellness crossover — implying systemic calm via a cream. Real cosmetic value is more pedestrian: antioxidant and anti-inflammatory phytochemistry comparable to better-studied botanicals like green tea or centella, with less robust skin-specific data and a higher price point.